Generic
Human Papillomavirus Quadrivalent
1 brands available in the market
At a glance
Human Papillomavirus Quadrivalent is indicated for girls and women 9-26 years and boys and men 9-45 years for prevention of cancers, genital warts and precancerous lesions caused by HPV types 6, 11, 16 and 18.
Description
Human Papillomavirus Quadrivalent vaccine is used for preventing diseases caused by HPV types 6, 11, 16 and 18. It is indicated for girls and women 9-26 years and boys and men 9-45 years. The vaccine contains recombinant L1 proteins that form virus-like particles (VLPs) and stimulate humoral immune responses.
Indications
Girls and Women (9-26 years):
- Cervical, vulvar, vaginal and anal cancer (HPV 16 & 18)
- Genital warts (HPV 6 & 11)
- CIN, VIN, VaIN & AIN (HPV 6, 11, 16 & 18)
Boys and Men (9-45 years):
- Anal, oropharyngeal and head and neck cancers (HPV 16, 18, 31, 33, 45, 52 & 58)
- Genital warts (HPV 6 & 11)
- AIN (HPV 6, 11, 16, 18, 31, 33, 45, 52 & 58)
Therapeutic class
Vaccines, Anti-sera & Immunoglobulin
Pharmacological class
HPV Vaccine
Pharmacology
HPV Quadrivalent vaccine contains L1 proteins of HPV types 6, 11, 16 and 18 produced by recombinant DNA technology, which form virus-like particles (VLPs). These VLPs act as antigens and generate HPV-specific antibodies, mediating humoral immune responses against anogenital diseases.
Mechanism of action
The vaccine stimulates the immune system through virus-like particles (VLPs) to produce antibodies against HPV types 6, 11, 16 and 18, which prevent future infection by these viruses.
Dosage
9 through 14 years:
- 2-dose: 0, 6-12 months (3rd dose needed if 2nd dose given before 5 months)
- 3-dose: 0, 2, 6 months
15 through 45 years:
- 3-dose: 0, 2, 6 months
Administration
Intramuscular injection only in the deltoid region of the upper arm or anterolateral area of the thigh. Shake well before use. Thorough agitation immediately before administration is necessary to maintain suspension. Do not dilute or mix with other vaccines.
Missed dose
If you miss a dose, take it as soon as possible and follow the schedule for subsequent doses. Consult your doctor.
Side effects
Most Common (≥10%) Local and Systemic Reactions:
- Injection-site pain (82.8-89.9%)
- Injection-site swelling (16.9-47.8%)
- Injection-site erythema (16.9-34.1%)
- Headache (11.4-14.6%)
Precautions & warnings
Precautions:
- Observe for 15 minutes after administration to prevent syncope
- Syncope with tonic-clonic movements has been reported
- Immunosuppressive therapy may reduce immune response
- Caution in severe allergic reactions to yeast or previous dose
Contraindications
Contraindications:
- Severe allergic reactions to yeast or previous dose
- Hypersensitivity
Drug interactions
Drug Interactions:
- Immunosuppressive therapy (irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids) may reduce immune response to vaccine
- Do not dilute or mix with other vaccines
Food interactions
No food interaction found/established.
Use in pregnancy
Use in Pregnancy: Category B. Animal studies show no impaired fertility or fetal harm at recommended human dose. No adequate studies in pregnant women; use only if clearly needed.
Use in lactation
Use in Lactation: It is not known whether HPV Quadrivalent is excreted in human milk; caution should be exercised as many drugs are excreted in human milk.
Pediatric use
Safety and effectiveness not established in children below 9 years.
Geriatric use
Safety and effectiveness not evaluated in geriatric population (65 years and over).
Renal / hepatic impairment
No specific data for renal or hepatic impairment.
Overdose effects
Reports of administration of higher than recommended doses; adverse event profile comparable to recommended single doses.
Storage conditions
Store at +2°C to +8°C. Do not freeze. Protect from light. Administer as soon as possible after removal from refrigeration.
Chemical structure
HPV Quadrivalent Vaccine